Loading
A phase 1/2 trial of Pembrolizumab, Enfortumab vedotin and Carboplatin in advanced solid tumours, run by Astellas Pharma Global Development, Inc., now recruiting.
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors is a phase 1/2 interventional study registered as NCT07287995 by Astellas Pharma Global Development, Inc., with 428 participants planned, started 2026-02-05 and due to reach its primary completion in 2029-06-30. Interventions recorded: ASP2998, Pembrolizumab, Enfortumab Vedotin and Carboplatin.
Shares Astellas, Carboplatin, Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Enfortumab vedotin, Astellas, Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Enfortumab vedotin, Astellas, Pembrolizumab and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Enfortumab vedotin, Astellas, Pembrolizumab and the tag pipeline.
Shares Enfortumab vedotin, Astellas and the tag pipeline.